Legacy Flip

611article: Immuno-Oncology Takes Center Stage at ASCO 2014
611article: Highest Response Rate to Date With a Third-Line VEGF Inhibitor, Pazopanib, in Metastatic Renal Cell Carcinoma
611article: Molecular Diversity of CLL
611article: PMO and the PMC – A Collaboration to Advance Precision Medicine
611article: The Evolution of Personalized Medicine in Oncology
611article: Implementing Global Healthcare: Partners In Health and the Rwandan Cancer Center Initiative
611article: Androgen Suppression in Castration-Resistant Prostate Cancer
611article: Personalizing Value-Based Medicine
611article: Bevacizumab Improves Survival in Patients With Metastatic Colorectal Cancer
611article: Phi Index Can Select Patients With Prostate Cancer for Active Surveillance
611article: Updated NCCN Guidelines for Non-Hodgkin Lymphoma Note Controversy Related to B-Cell Disease Management: Cell of Origin May Soon Influence Treatment Decisions
611article: New Molecular Test to Monitor Breast Cancer Recurrence by Sequencing Circulating Tumor Cells
611article: PARP Inhibitor Active in Recurrent BRCA-Positive Ovarian Cancer
610article: The Affordable Care Act and Cancer Patients – Winners and Losers in an Unsteady Paradigm Shift: Part 2 The Conclusion of an Analysis of the ACA by Kip Piper, MA, FACHE
610article: It’s About Time: Monoclonal Antibodies for Multiple Myeloma
610article: Investigational Angiogenesis Inhibitor Improves Survival as Second-Line Treatment in Gastric Cancer
610article: Treatment Paradigm for NSCLC May Be Shifting
610article: Molecular Monitoring Can Provide Treatment Guidance in CML
610article: Therapy for Castration-Resistant Prostate Cancer: Use Disease State as the Guide
610article: The Affordable Care Act: Where Are We Now, What’s the Future?
610article: New Melanoma Guideline Adds BRAF Inhibitor, MEK Inhibitor to First-Line Systemic Therapy Options
610article: Routine Cervical Cancer Screening Warranted Beyond Age 64
610article: 14 New Genetic Markers Predict Risk for Prostate Cancer
610article: Promise of Personalized Care Hinges on Reimbursement Reform: Oncologists Must Lead the Way
610article: A Win for Pediatric Cancer Research: The Gabriella Miller Kids First Research Act and Smashing Walnuts Foundation
610article: Perspectives on the Landscape of Personalized Medicine

An Interview with Gail E. Herman, MD, PhD; Barbara L. McAneny, MD; and Charles L. Sawyers, MD

610article: Anti–PD-1/PD-L1 Therapy: New Immunotherapy Options for Patients With a Variety of Cancers
610article: A Breakthrough Treatment for ALL and CLL: The New Biologic Agent, CTL019

An Interview With David L. Porter, MD, of the University of Pennsylvania

610article: JAK2 V617F in a Patient With AML
610article: The Full Spectrum of Knowledge Driving Personalized Medicine
609article: Introducing Immunotherapy in Oncology: A 4-Part Supplement Series to Personalized Medicine in Oncology
609article: Sequential Therapy for Renal Cell Carcinoma
609article: Review: The Role of the PD-1 Pathway in Immunotherapy
609article: Checkpoint Inhibition of PD-1: The Promise of Pembrolizumab (MK-3475) and Beyond
609article: The New Generation of Immunotherapies A Focus on the PD-1 Pathway
608article: The Affordable Care Act and Cancer Patients – Winners and Losers in an Unsteady Paradigm Shift
608article: Molecular Therapy Beyond Sorafenib in HCC: New Pathways, Targets Being Explored
608article: Promising Vaccine Combination Identified for Patients With Metastatic Pancreatic Cancer
608article: Immunotherapy Holds Promise to Extend Survival in GI Cancers
608article: The Cancer Genome Atlas Project Explores Bladder Cancer
608article: Enzalutamide Extends Survival in Previously Untreated Metastatic Prostate Cancer
608article: Angiotensin System Inhibitors Extend Survival in Patients With Metastatic Renal Cell Carcinoma
608article: Switching From IV to Subcutaneous Rituximab Saves Staff Time and Money
608article: Surveillance Scanning in Transformed Indolent Lymphoma Is of Limited Clinical Benefit
608article: Peripheral T-Cell Lymphoma Represents High Clinical Burden, Resource Utilization, and Costs
608article: Readmission Following Stem Cell Transplant Decreases Survival
608article: Choosing Wisely Initiative Aims to Lower Cost, Improve Quality of Care
608article: Clinical Practice Guidelines Should Include Patient’s Preferences
608article: NCI Pilot Trial to Assess Value of Genetic Sequencing for Improving Patient Outcomes
608article: ASCO Proposes New Model for Reimbursement by Medicare for Cancer Care
608article: Empowering the Practice of Personalized Medicine: The Evolving Role of Pathology in Cancer Diagnostics
608article: Family With a Risk of Cancer Tries to Change Its Destiny
608article: Case Study: Molecular Profiling in Acute Myeloid Leukemia
608article: KIT Genetic Mutation in a Melanoma Patient
608article: The Value of Personalized Medicine in Oncology
606article: New Technology Diffusion Essential to Personalized Medicine: An Interview With Dr Gary Owens
606article: Hematologists Often Ignore Treatment and Monitoring Recommendations
606article: Novel CAR-T Therapy Topped the News at ASH
606article: FIRST Trial Shows Value of Continued Use of Lenalidomide in Newly Diagnosed Myeloma Patients
606article: Ph+ CML: Deep Molecular Response Achieved and Sustained More Often With Nilotinib
606article: More Transplants Made Possible Through Haploidentical Donors
606article: Anti-CD20 Agent Improves Outcomes in Elderly/Unfit Patients With Chronic Lymphocytic Leukemia
606article: ALL: Genetics Providing New Insights Into Signaling Pathways and Treatment Targets
606article: Novel Anti-CD20 Antibody Superior to Rituximab on Progression-Free Survival in Unfit CLL Patients
606article: Idelalisib Improves Outcomes in Heavily Pretreated CLL Patients
606article: Hematologists Question Panel About Guidelines and Performance Measures
606article: Lenalidomide as Maintenance in Transplant Myeloma Population Still Debated
606article: Case Study: Use of Biomarkers in Multiple Myeloma
606article: News from the 2013 San Antonio Breast Cancer Symposium
606article: Need for Innovative Strategies for Quality Care Will Continue to Grow
606article: Partners HealthCare Center for Personalized Genetic Medicine: Utilizing Genetics and Genomics to Improve Care of Patients

An Interview With Scott T. Weiss, MD, MS, and Heidi L. Rehm, PhD

606article: The Importance of the Multidisciplinary Team in Personalizing Care
606article: PROGRESS REPORT: Implementation of ASCO’s Blueprint for Transforming Clinical and Translational Cancer Research
605article: Preserving Personalized Medicine – Holding Fast to Healthcare’s Governing Dynamics
605article: Idelalisib and Ibrutinib Are Promising B-Cell Receptor Signaling Inhibitors in B-Cell Malignancies
605article: Genomics of Acute Myeloid Leukemia Explored
605article: T-DM1 Prolongs Survival in Advanced HER2-Positive Breast Cancer
605article: Second-Generation ALK Inhibitor Regresses CNS Metastasis in NSCLC
605article: MPDL3280A in Advanced NSCLC
605article: ObamaCare 2016: Happy Yet? The website problems were finally solved. But the doctor shortage is a nightmare
605article: You Also Can’t Keep Your Doctor.
605article: Case Study: Lower-Risk Myelodysplastic Syndromes
605article: TAILORx: A Trial Design Toward Our Goal of Personalized Medicine
605article: Personalized Medicine and the Biopharmaceutical Industry: The Marrying of Science, Research, and Policy

An Interview With Dr William Chin of the Pharmaceutical Research and Manufacturers of America

605article: Predicting Response to EGFR-Targeting mAbs in Colorectal Cancer – Is the KRAS Mutation Test Sufficient?
605article: Happy Holidays From the PMO Editorial Board
603article: PMO Proudly Announces Dr Sanjiv S.Agarwala to Join Dr Al Benson as Co-Editor in Chief
603article: Bench to Bedside, Gene to Drug Discovery Defines New Era of Precision Medicine
603article: Gene Expression Tests Using Bronchial, Nasal Epithelium Under Development for Early Detection of Lung Cancer
603article: Personalized Cancer Treatment: Combination Therapies May Be Key to Hitting Tumor Heterogeneity
603article: Practical Problems Must Be Overcome to Move Personalized Medicine Forward in Oncology
603article: Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer
603article: VA Takes Lead Role in Using Informatics to Validate and Translate Biomarkers
603article: Next-Generation Sequencing Identifies Actionable Genomic Alterations in Solid Tumors
603article: Biomarker Development and Validation Crucial to Use of Emerging Treatments in Solid Tumors and Hematologic Malignancies
603article: To PARP or Not to PARP – What Is the Question? Part 2 Perspective on the First “Disappointment” With a New Drug Class
603article: Personalizing Therapy in the Management of Recurrent Non–Small Cell Lung Cancer: Case Study of a Patient With an EGFR Mutation
603article: Role of Radiation and Imaging in DCIS Explained
603article: Molecular Profiling in Breast Cancer: Still Not Ready for the Clinic
603article: Multiplex Genetic Assays Identify Mutations Beyond BRCA1/2 in 10% of Patients at Risk for Breast Cancer